Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)
(2006) In European Journal of Cancer 42(18). p.3178-3185- Abstract
- Background: Continuous ligand depletion of endocrine responsive tumours may enhance resistance to therapy. Intermittent treatment with tamoxifen (T) was considered to mimic (incomplete) ligand depletion and reintroduction. Furthermore it was postulated that alternating tamoxifen with a non-cross resistant endocrine modality could (further) postpone hormone resistance. Patients and methods: Postmenopausal patients with advanced breast cancer who did not progress after 4 months of first line T therapy were randomised to continue T (40 mg daily) or to 2 monthly intermittent T or intermittent/alternated T and medroxyprogesterone acetate (MPA, 300 mg daily). At progression during break or during MPA, T should be reintroduced. Endpoints of the... (More)
- Background: Continuous ligand depletion of endocrine responsive tumours may enhance resistance to therapy. Intermittent treatment with tamoxifen (T) was considered to mimic (incomplete) ligand depletion and reintroduction. Furthermore it was postulated that alternating tamoxifen with a non-cross resistant endocrine modality could (further) postpone hormone resistance. Patients and methods: Postmenopausal patients with advanced breast cancer who did not progress after 4 months of first line T therapy were randomised to continue T (40 mg daily) or to 2 monthly intermittent T or intermittent/alternated T and medroxyprogesterone acetate (MPA, 300 mg daily). At progression during break or during MPA, T should be reintroduced. Endpoints of the study were progression free survival (PFS), time to resistance to tamoxifen and overall survival (OS). Results: Of 593 registered patients, 276 were randomised. After 8 years follow-up the median PFS for continuous T, intermittent T and intermittent/alternated T and MPA was 11.0 (8.1-15.2), 8.0 (6.2-12.4) and 10.8 (7.1-16.7) months, respectively (NS). Resistance to tamoxifen was established only in 84%, 70% and 55% of patients in the three treatment arms, respectively The median times from randomisation to resistance to tamoxifen were 12.5 (9.1-21.1), 13.2 (8.8-19.8) and 24.0 (16.9-60.9) months, respectively (p < 0.001), without translation in differences in survival times. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/679462
- author
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- endocrine therapy, alternated, advanced breast cancer, intermittent endocrine therapy, tamoxifen medroxyprogesterone acetate, randomised, study
- in
- European Journal of Cancer
- volume
- 42
- issue
- 18
- pages
- 3178 - 3185
- publisher
- Elsevier
- external identifiers
-
- wos:000243304900022
- scopus:33845224929
- ISSN
- 1879-0852
- DOI
- 10.1016/j.ejca.2006.08.020
- language
- English
- LU publication?
- yes
- id
- 70c6ffd7-95e0-42df-92a3-276281f72f58 (old id 679462)
- date added to LUP
- 2016-04-01 12:36:43
- date last changed
- 2022-01-27 07:28:23
@article{70c6ffd7-95e0-42df-92a3-276281f72f58, abstract = {{Background: Continuous ligand depletion of endocrine responsive tumours may enhance resistance to therapy. Intermittent treatment with tamoxifen (T) was considered to mimic (incomplete) ligand depletion and reintroduction. Furthermore it was postulated that alternating tamoxifen with a non-cross resistant endocrine modality could (further) postpone hormone resistance. Patients and methods: Postmenopausal patients with advanced breast cancer who did not progress after 4 months of first line T therapy were randomised to continue T (40 mg daily) or to 2 monthly intermittent T or intermittent/alternated T and medroxyprogesterone acetate (MPA, 300 mg daily). At progression during break or during MPA, T should be reintroduced. Endpoints of the study were progression free survival (PFS), time to resistance to tamoxifen and overall survival (OS). Results: Of 593 registered patients, 276 were randomised. After 8 years follow-up the median PFS for continuous T, intermittent T and intermittent/alternated T and MPA was 11.0 (8.1-15.2), 8.0 (6.2-12.4) and 10.8 (7.1-16.7) months, respectively (NS). Resistance to tamoxifen was established only in 84%, 70% and 55% of patients in the three treatment arms, respectively The median times from randomisation to resistance to tamoxifen were 12.5 (9.1-21.1), 13.2 (8.8-19.8) and 24.0 (16.9-60.9) months, respectively (p < 0.001), without translation in differences in survival times.}}, author = {{Beex, L. and Rose, Carsten and Mouridsen, H. and Jassem, J. and Nooij, M. and Estape, J. and Paridaens, R. and Piccart, M. and Gorlia, T. and Lardenoije, S. and Baila, L.}}, issn = {{1879-0852}}, keywords = {{endocrine therapy; alternated; advanced breast cancer; intermittent endocrine therapy; tamoxifen medroxyprogesterone acetate; randomised; study}}, language = {{eng}}, number = {{18}}, pages = {{3178--3185}}, publisher = {{Elsevier}}, series = {{European Journal of Cancer}}, title = {{Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)}}, url = {{http://dx.doi.org/10.1016/j.ejca.2006.08.020}}, doi = {{10.1016/j.ejca.2006.08.020}}, volume = {{42}}, year = {{2006}}, }